The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 09, 2024
Filed:
May. 25, 2022
Synarc Research Laboratory (Beijing) Ltd., Beijing, CN;
Hebei Yanda Ludaopei Hospital, Langfang, CN;
Hui Wang, Beijing, CN;
Man Chen, Beijing, CN;
Aixian Wang, Beijing, CN;
Meiwei Gong, Beijing, CN;
Xueying Wu, Beijing, CN;
Junyi Zhen, Beijing, CN;
Qing Du, Beijing, CN;
Ya Guo, Beijing, CN;
Synarc Research Laboratory (Beijing) Ltd., Beijing, CN;
HEBEI YANDA LUDAOPEI HOSPITAL, Sanhe, CN;
Abstract
The present invention provides a detection reagent and therapeutic target for B cell tumor after targeted therapy and related applications. The reagent composition comprises 3 groups of antibodies, with the first group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD24 an antibody, an anti-CD20 antibody, an anti-CD81 antibody, an anti-CD45 antibody; the second group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD20 antibody, an anti-CD72 antibody, an anti-CD45 antibody; and the third group of antibodies including an anti-cytoplasmic CD79a antibody. The reagent composition of the present invention can be applied for the detection of B-lymphocyte tumors after targeted therapy by flow cytometry.